Accelerate DPI Clinical Success with Innovative De-Risking Strategy
Discover the comprehensive session of ‘Empowering the Path to Clinical: Innovative Strategies for De-Risking DPI Product Development’ from RDD 2024.
Novel Aerosol Apparatus for Inhaler Testing in OINDPs
Explore a case study for UniDose in the development of a novel aerosol collection apparatus for dissolution testing of orally inhaled drugs.
Nanopharm Value Creation with OINDP Innovation
Discover Nanopharm’s pre-clinical OINDP solutions using SmartTrack for cutting-edge MDI development, transforming respiratory drug research.
Dual Excipient Integration in Dry Powder Inhaler Products
Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.
Nanopharm Newsletter May 2023
Explore Nanopharm’s SmartTrack™ for OINDPs and uncover the role of PBPK in nasal drug delivery.
Propellant Aerosols & Transition to Low GWP pMDIs
Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.
Primary Crystallization’s Influence on Fluticasone DPIs
Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.
Albuterol & Low GWP Propellants: Deposition Prediction
Explore predictions of regional deposition and systemic exposure of Albuterol Sulfate with low global warming potential propellants in pMDIs.
Assessing Particle Size in DPIs with Spraytec & Unidose
Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.
Pulmonary Fate of Fluticasone: Challenges Met
Nanopharm investigate the pulmonary effect of Fluticasone and related compounds, addressing physiologic and pharmacokinetic challenges.
